Microbix antigens are at the core of the world’s leading infectious disease assays. Proficiency programs trust our samples to assess the quality of clinical laboratory tests. Our expertise in cell biology is reflected in LumiSort, an animal reproductive product and Kinlytic, a biopharmaceutical used to treat blood clots.

MOLECULAR DIAGNOSTICS

See Microbix’ products for this emerging market.

KINLYTIC™

Learn about this thrombolytic drug here.

INFECTIOUS DISEASE ANTIGENS

See our expanding menu of antigens here.

LUMISORT™ TECHNOLOGY

Find out more about the revolutionary technology here.

Latest from the Newsroom

  • Microbix Announces First Shipment of Bioreactor Antigen

    Customer Validation of New Manufacturing Process Completed TORONTO: September 13, 2017 – Microbix Biosystems Inc. (TSX: MBX), a developer and marketer of biological products and technologies, announces its first full-scale shipment of antigen produced using its new bioreactor manufacturing process, following customer validation. Microbix’ revenues......

  • Microbix to Amend Share Purchase Warrant Terms

    TORONTO August 24 2017 – Microbix Biosystems Inc. (TSX: MBX), a developer and marketer of biological products and technologies, announces it has applied to the TSX to amend the terms of 1,500,000 common share purchase warrants (the “Warrants”) issued in connection with a non-brokered private......

  • Microbix Reports Record Third Quarter & Nine Month Sales – Year-Over-Year Sales Growth Exceeding 20%

    TORONTO, August 14, 2017 – Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, today reports financial results for its fiscal third quarter and nine months ended June 30, 2017 (“Q3” and “9 Mo.”). Third Quarter Financial Results Total Q3 revenue was......